Literature DB >> 9404557

In vivo relevance of CD30 in atopic dermatitis.

M Caproni1, B Bianchi, M M D'Elios, M De Carli, A Amedei, P Fabbri.   

Abstract

CD30 expression was evaluated by immunohistochemistry in lesional skin biopsies of eight patients with active atopic dermatitis (AD) and three patients with allergic contact (nickel-induced) dermatitis (ACD). CD30 expression was also assessed in a large panel of CD4+ and CD8+ T-cell clones generated from the skin biopsies of four patients with AD. Finally, the levels of soluble CD30 (sCD30) were measured in the serum of 41 patients with AD, 19 patients with ACD, and 60 healthy controls. In all specimens of lesional AD skin, where the great majority of infiltrating cells were CD4+ T cells, remarkable numbers of cells were CD30+, whereas virtually no CD30+ cells were found in the skin of patients with ACD. In CD4+ T-cell clones generated from the lesional AD skin, most of which produced both interleukin (IL)-4 and interferon-gamma (IFN-gamma) (Th0-like cells) or IL-4 and IL-5, but not IFN-gamma (Th2-like cells), CD30 expression directly correlated with the ability to produce IL-4 and IL-5, but was inversely related to IFN-gamma production. High levels of sCD30 (correlated with disease activity: r = 0.618) were detected in the serum of most AD patients, whereas there was no increase of sCD30 levels in the serum of patients with ACD. These data support the view that Th0/Th2-type responses predominate in the skin of patients with AD and suggest that the presence of CD30+ T cells in tissues and/or increased levels of sCD30 in biologic fluids are indicative of Th2-dominated responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9404557     DOI: 10.1111/j.1398-9995.1997.tb00177.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  8 in total

1.  Regulation of CD30 antigen expression and its potential significance for human disease.

Authors:  M E Kadin
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26.

Authors:  N Katoh; S Hirano; M Suehiro; K Ikenaga; T Yamashita; N Sugawara; H Yasuno
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 3.  Deciphering CD30 ligand biology and its role in humoral immunity.

Authors:  Mary K Kennedy; Cynthia R Willis; Richard J Armitage
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

4.  Thiols decrease cytokine levels and down-regulate the expression of CD30 on human allergen-specific T helper (Th) 0 and Th2 cells.

Authors:  A Bengtsson ; M Lundberg; J Avila-Cariño; G Jacobsson; A Holmgren; A Scheynius
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

5.  Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion.

Authors:  Marie Fischer; Ilkka T Harvima; Ricardo F S Carvalho; Christine Möller; Anita Naukkarinen; Gunilla Enblad; Gunnar Nilsson
Journal:  J Clin Invest       Date:  2006-09-07       Impact factor: 14.808

Review 6.  Beyond CD19 CAR-T cells in lymphoma.

Authors:  Wingchi K Leung; Adanma Ayanambakkam; Helen E Heslop; LaQuisa C Hill
Journal:  Curr Opin Immunol       Date:  2021-11-17       Impact factor: 7.486

7.  Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.

Authors:  Carlos A Ramos; Natalie S Grover; Anne W Beaven; Premal D Lulla; Meng-Fen Wu; Anastasia Ivanova; Tao Wang; Thomas C Shea; Cliona M Rooney; Christopher Dittus; Steven I Park; Adrian P Gee; Paul W Eldridge; Kathryn L McKay; Birju Mehta; Catherine J Cheng; Faith B Buchanan; Bambi J Grilley; Kaitlin Morrison; Malcolm K Brenner; Jonathan S Serody; Gianpietro Dotti; Helen E Heslop; Barbara Savoldo
Journal:  J Clin Oncol       Date:  2020-07-23       Impact factor: 50.717

8.  Cytological diagnostic features of late breast implant seromas: From reactive to anaplastic large cell lymphoma.

Authors:  Arianna Di Napoli; Giuseppina Pepe; Enrico Giarnieri; Claudia Cippitelli; Adriana Bonifacino; Mauro Mattei; Maurizio Martelli; Carlo Falasca; Maria Christina Cox; Iolanda Santino; Maria Rosaria Giovagnoli
Journal:  PLoS One       Date:  2017-07-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.